Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
Expert Opin Pharmacother. 2014 Apr;15(5):681-700. doi: 10.1517/14656566.2014.885952. Epub 2014 Feb 28.
Expert Opin Pharmacother. 2014.
PMID: 24579888
Review.
Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
Yndestad S, Austreid E, Svanberg IR, Knappskog S, Lønning PE, Eikesdal HP.
Yndestad S, et al. Among authors: austreid e.
Oncotarget. 2017 Jun 20;8(25):41227-41241. doi: 10.18632/oncotarget.17167.
Oncotarget. 2017.
PMID: 28476032
Free PMC article.
Item in Clipboard
High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.
Yndestad S, Austreid E, Knappskog S, Chrisanthar R, Lilleng PK, Lønning PE, Eikesdal HP.
Yndestad S, et al. Among authors: austreid e.
Breast Cancer Res Treat. 2017 May;163(1):177-190. doi: 10.1007/s10549-017-4160-5. Epub 2017 Feb 17.
Breast Cancer Res Treat. 2017.
PMID: 28213783
Free PMC article.
Item in Clipboard
Divergent Activity of the Pseudogene PTENP1 in ER-Positive and Negative Breast Cancer.
Yndestad S, Austreid E, Skaftnesmo KO, Lønning PE, Eikesdal HP.
Yndestad S, et al. Among authors: austreid e.
Mol Cancer Res. 2018 Jan;16(1):78-89. doi: 10.1158/1541-7786.MCR-17-0207. Epub 2017 Oct 11.
Mol Cancer Res. 2018.
PMID: 29021233
Item in Clipboard
Cite
Cite